News & Information
PhRMA: Sunshine Not Driving Docs Indoors
Written by Editor   
Friday, April 11, 2014 11:00 AM

Doctors haven't disengaged from drug companies in the months since the tracking of financial relationships between them started, several pharmaceutical executives said.  The Physician Payments Sunshine Act required drug companies to track gifts and other payments to physicians starting August 1, making them public later this year, but those ties have pretty much stayed put.  Different leaders of the drug industry said at the annual meeting of the Pharmaceutical Research and Manufacturers of America (PhRMA).  "We've seen virtually no change in the way we interact with physicians," Pfizer CEO Ian Read said at a press conference.

HHS Secretary Kathleen Sebelius Resigns
Written by Editor   
Thursday, April 10, 2014 10:30 PM

Health and Human Services Secretary Kathleen Sebelius is resigning, ending her 5-year term that was marred by the problem-plagued rollout of the Affordable Care Act (ACA), President Obama's key domestic policy achievement, a White House official said Thursday.

Sebelius quit her cabinet post just 1 week after the end of the first enrollment period for the ACA. She announced today that 7.5 million people had enrolled for health coverage under the new law.

Sylvia Mathews Burwell, the director of the Office of Management and Budget, will be nominated to replace Sebelius, officials said.

ACA Answers Member Questions About Network - EmpowerChiro (Family Health America, LC)
Written by Editor   
Thursday, April 10, 2014 01:00 PM
This information is provided by the American Chiropractic Association in response to several requests for information regarding the chiropractic network, EmpowerChiro.  Members may call the Company (800-819-9571) to obtain more information.  ACA cautions members, as always, to consult an attorney when there are questions regarding contractual matters and to thoroughly consider all aspects of network participation for their clinic.  Finally, ACA reminds all providers that communication between competitors regarding participation with and/or payment from managed care organizations is a matter subject to antitrust regulations.
The following information is provided as a courtesy to assist providers' understanding as they research information about EmpowerChiro, and is not intended to either encourage or discourage provider participation.  Each provider should make an individual, fully-informed decision.  The following information was derived from information released from EmpowerChiro and has been reviewed by the Company:
Flu Drugs Challenged in Full Data Review
Written by Editor   
Thursday, April 10, 2014 01:00 AM

Two major anti-influenza drugs have more limited benefits and greater risks than was previously thought, according to new reviews -- the first to have access to all the clinical trial data.  The reviews of the neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) are the culmination of several years of often-controversial research.  They call into question the value of the medications both as treatment and prophylaxis, the way drugs are currently approved, and decisions to stockpile the drugs at a cost of billions.

The reviews themselves are unprecedented: The drugmakers turned over thousands of pages of previously closely held corporate data on a host of studies. Taken together, the data show that "effectiveness has been overplayed and harms underplayed."

Welcome to News and Information
Wednesday, April 09, 2014 11:57 AM
Welcome to our new news and information structure.  It will take us a few days to populate this particular news section with news.  In the mean time be sure to check our Communications Archives for news from March 2014, and before.
<< first < Prev 241 242 243 244 245 246 247 248 249 250 Next > last >>

Page 249 of 251